Results 21 to 30 of about 13,691 (157)

Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer

EBioMedicine, 2016
Background: In the Prostate Cancer Prevention Trial, finasteride selectively suppressed low-grade prostate cancer and significantly reduced the incidence of prostate cancer in men treated with finasteride compared with placebo.
Jeri Kim, John W. Davis, Eric A. Klein, Cristina Magi-Galluzzi, Yair Lotan, John F. Ward, Louis L. Pisters, Joseph W. Basler, Curtis A. Pettaway, Andrew Stephenson, Elsa M. Li Ning Tapia, Eleni Efstathiou, Xuemei Wang, Kim-Anh Do, J. Jack Lee, Ivan P. Gorlov, Lana A. Vornik, Ashraful M. Hoque, Ina N. Prokhorova, Howard L. Parnes, Scott M. Lippman, Ian M. Thompson, Powel H. Brown, Christopher J. Logothetis, Patricia Troncoso   +24 more
doaj   +1 more source

Occupational Physical Activity Is Negatively Associated With Semen Quality

Andrology, EarlyView.
ABSTRACT Background Lifestyle factors have been associated with semen quality and have been implicated in the reported global decline in semen parameters. Moderate physical activity has been linked to improved semen quality; however, the association between occupational physical activity and semen quality is limited.
Michal Efrat, Sharon Barak, Anat Stein, Haim Pinkas, Ron Unger, Ruth Birk   +5 more
wiley   +1 more source

The ‘Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease’ (PATROL) study

BJU International, EarlyView.
Background Inherited (germline) pathogenic and likely pathogenic variants (gPVs) in key genes associated with increased risk of prostate cancer (PCa) now warrant more attentive PCa screening per National Comprehensive Cancer Network (NCCN) guidelines—e.g., BRCA2, HOXB13, ATM, BRCA1, MSH2, MSH6, CHEK2 and TP53.
Heather H. Cheng, Kara N. Maxwell, Keyan Salari, Matthew R. Cooperberg, Kristin Follmer, Joanne M. Jeter, Grace Jun, Daniel J. Lee, Hiten D. Patel, Edward M. Schaeffer, Alexandra O. Sokolova, Erika M. Wolff, Daniel W. Lin   +12 more
wiley   +1 more source

Current Approaches to Support Patients to Withdraw From Image and Performance Enhancing Drugs

Clinical Endocrinology, EarlyView.
ABSTRACT Image and performance‐enhancing drugs (IPEDs) include agents such as androgens, growth hormone, and erythropoietin, which are used to enhance appearance and physical performance. Androgens, also known as anabolic‐androgenic steroids (AAS), are the most used IPEDs worldwide.
Elizabeth Hyams, Bonnie Grant, Richard Quinton, Channa N. Jayasena   +3 more
wiley   +1 more source

Persistent Sexual, Emotional, and Cognitive Impairment Post-Finasteride

American Journal of Men's Health, 2015
Finasteride is a synthetic 5-α reductase inhibitor, which prevents the conversion of testosterone to dihydrotestosterone and has been used for more than 20 years in the treatment of male pattern hair loss.
Christine Anne Ganzer PhD, Alan Roy Jacobs MD, Farin Iqbal   +2 more
doaj   +1 more source

Absence of Interaction Between 5α‐Reductase Inhibitors and Glucocorticoids on Incidence of Myocardial Infarction in People With Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims People with Type 2 diabetes experience higher cardiometabolic risk, and both synthetic glucocorticoids and use of 5α‐reductase inhibitors have been individually linked to increased risk of myocardial infarction. We tested whether the increase in risk is exacerbated by co‐prescription of both drugs.
Haolan Tu, Chengsheng Ju, Stuart J. McGurnaghan, Luke A. K. Blackbourn, Scottish Diabetes Research Network Epidemiology Group, Peter Hanlon, Robert Lindsay, David McAllister, John Petrie, Naveed Sattar, Brian Kennon, Sam Philip, Scott Cunningham, Huan Wang, William Berthon, Helen Colhoun, Paul McKeigue, Sarah Wild, Ewan R. Pearson, Li Wei, Ruth Andrew   +20 more
wiley   +1 more source

Comparison between dutasteride and finasteride in hair regrowth and reversal of miniaturization in male and female androgenetic alopecia: a systematic review

Dermatology Reports
Nowadays androgenetic alopecia (AGA) has become a common concern of affected subjects of both sexes. Finasteride is approved by the Food and Drug Administration for the treatment of male AGA.
Almuntaserbellah Almudaimeegh, Hanadi AlMutairi, Fatimah AlTassan, Yomna AlQuraishi, Khalid Nabil Nagshabandi   +4 more
doaj   +1 more source

The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on biopsy: Results of a randomized trial.

PLoS ONE, 2018
BackgroundFinasteride, a 5-alpha reductase inhibitor may have effects on biomarkers such as prostate-specific antigen (PSA) that could be leveraged to improve screening.ObjectiveTo determine the predictive characteristics of biomarkers for prostate ...
Javier Hernandez, Jonathan Gelfond, Martin Goros, Michael A Liss, Yuanyuan Liang, Donna Ankerst, Ian M Thompson, Robin J Leach   +7 more
doaj   +1 more source

Treatment Patterns in Pediatric Hidradenitis Suppurativa: Time to Treatment Initiation, Initial Treatment, and Time to Switching

Pediatric Dermatology, EarlyView.
ABSTRACT Background Hidradenitis suppurativa (HS) causes significant morbidity in children. Treatment patterns across sex, race, and ethnicity in pediatric HS have not been thoroughly evaluated. We aim to characterize treatment patterns in pediatric HS, including (1) time to treatment initiation, (2) first prescribed HS treatment, and (3) time to ...
Shaliz Aflatooni, Andrea Ure, Kimberly Smart, Julian A. Cortes, Gabriela Palma, Nicole Johnsen, Yvonne Nong, April W. Armstrong   +7 more
wiley   +1 more source

Efficacy of finasteride for treating patients with androgenetic alopecia who are pileous in other areas: A pilot study in Japan

Indian Journal of Dermatology, 2014
Background: Androgenetic alopecia (AGA) involves androgen-dependent hair loss and finasteride is an established treatment for the disease. However, reports of the influence of finasteride on hair growth in other areas of the body are lacking.
Toru Inadomi
doaj   +1 more source